Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Jeffrey A. JonesDivision of Hematology, The Ohio State University, Columbus, OH, USA

Amy S. RuppertDivision of Hematology, The Ohio State University, Columbus, OH, USA

Weiqiang ZhaoDepartment of Pathology, The Ohio State University, Columbus, OH, USA

Thomas S. LinGlaxoSmithKline, Philadelphia, PA, USA

Kanti RaiDivision of Hematology and Oncology, Long Island Jewish Medical Center, New Hyde Park, NY, USA

Bercedis PetersonDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA

Richard A. LarsonDepartment of Medicine, University of Chicago, Chicago, IL, USA

Guido MarcucciDivision of Hematology, The Ohio State University, Columbus, OH, USA

Nyla A. HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH, USA

John C. ByrdDivision of Hematology, The Ohio State University, Columbus, OH, USACorrespondence[email protected]

Your download is now in progress and you may close this window